已收盤 07-18 16:00:00 美东时间
-0.070
-4.24%
Drone stocks are taking off after hours Thursday after Defense Secretary Pete Hegseth issued new orders to fast-track drone manufacturing and deployment.
07-11 05:17
Autonomix Medical, Inc. (NASDAQ: AMIX) has published the latest CEO Corner segment on its website, where CEO Brad Hauser discusses the planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial. The company specializes in advancing precision nerve-targeted treatments, utilizing a first-in-class platform technology capable of detecting and differentiating neural signals with high sensitivity. Initially focused on treating...
07-07 12:30
Shares of Venus Concept Inc. (NASDAQ:VERO) rose sharply in today's pre-market t...
06-30 18:39
Autonomix Medical, Inc. has enrolled the first patient in its PoC 2 phase, expanding its technology beyond pancreatic cancer pain to address additional visceral cancers via the Celiac Plexus, doubling the addressable market. This phase builds on PoC 1's success, aiming to enhance clinical and commercial potential while targeting a broader range of pain conditions through innovative nerve ablation techniques.
06-30 12:30
Autonomix Medical Inc. announced the issuance of U.S. Patent No. 12,279,889 B2 by the USPTO, supporting its mission to advance minimally invasive nerve-focused treatments for high-need conditions. The patent covers systems and methods for locating, monitoring, and mapping electrophysiological signals during neuromodulation or denervation procedures, as well as tools to access small vessels for treatment of cancerous tumors and associated pain. Th...
06-27 12:00
Follow-on study ("PoC 2") builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technologyExpansion
06-05 20:49
<p>The company has received ethics committee authorization to expand its clinical trial to evaluate its proprietary ablation technology for visceral cancer pain, following successful results in pancreatic cancer pain. Patient enrollment for the PoC 2 phase begins in June 2025, supporting the company's strategy to grow through multiple indications and create long-term value. The technology holds potential for broader applications, including oncolo...
06-05 12:45
Follow-on expansion phase expected to begin in Q2 2025THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on
05-13 21:25
Autonomix Medical (NASDAQ:AMIX) has priced an underwritten public offering of 1.37 million shares of its common stock at $6.54 per share, or pre-funded warrant units priced at $6.539 each, for an expe...
2024-11-25 16:48
Autonomix Medical press release (NASDAQ:AMIX): Q2 net losses of $2.8M. As of September 30, 2024, the company had cash of $5.2 million. More on Autonomix Medical, Inc. Autonomix rises after it reports ...
2024-11-12 02:01